German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...

The company has a market capitalization of $3.81 billion, a price-to-earnings ratio of -14.62 and a beta of 0.76. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $62.00.

In this article, we are going to take a look at where Merck & Co Inc. (NYSE:MRK) stands against other profitable value stocks to buy now. Matt Powers, Managing Partner at Powers Advisory Group ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

After hours: March 17 at 7:45:46 PM EDT Loading Chart for MRK ...

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.